Details for Patent: 8,952,018

Title:	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Abstract:	A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}ac- etamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2- -fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
Inventor(s):	Dumble; Melissa (Collegeville, PA), Kumar; Rakesh (Collegeville, PA), Laquerre; Sylvie (Collegeville, PA), Lebowitz; Peter (Collegeville, PA)
Assignee:	GlaxosmithKline LLC (Philadelphia`, PA)
Filing Date:	Mar 05, 2014
Application Number:	14/197,421
Claims:	1. A method of treating non-small cell lung cancer in a human in need thereof which comprises the administration of a therapeutically effective amount of (i) a compound of formula (I) ##STR00025## or a pharmaceutically acceptable salt or solvate thereof; and (ii) a compound of formula (II) ##STR00026## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein compound (I) is in the form of the dimethyisulfoxide solvate. 3. The method of claim 1, wherein compound (II) is in the form of the methanesulfonate salt. 4. The method of claim 1, wherein the non-small cell lung cancer is BRAF V600E mutant non-small cell lung cancer. 5. A method of treating non-small cell lung cancer in a human in need thereof which comprises the administration of a therapeutically effective amount of (i) a compound of formula (I) ##STR00027## or a pharmaceutically acceptable salt thereof; and (ii) a compound of formula (II) ##STR00028## or a pharmaceutically acceptable salt thereof.